News | October 13, 2010

FDA Clearance Announced for Imager for IGRT

October 13, 2010 — The U.S. Food and Drug Administration (FDA) has given 510(k) marketing clearance for the new RAD II kilovoltage (KV) imager for image-guided radiation therapy (IGRT). The RAD II KV imager can be mounted on virtually any model of linear accelerator.

The new KV imager, which is driven by TheraView software, provides high-quality X-ray images for maximum clinical efficiency and resolution. It is a product evolution of the legacy MV (mega-voltage) imaging product line. It seamlessly integrates with existing TheraView electronic portal imaging devices (EPIDs), as well as with linear accelerators that have other brands.

TheraView imaging systems are manufactured by Cablon Medical BV in The Netherlands, and the RAD II KV imager is manufactured by Acceletronics Digital Imaging LLC. in the United States. The TheraView KV imager is distributed and serviced by Acceletronics Inc., Radiology Oncology Systems (ROS) and Cablon.

For more information: www.theraviewusa.com

Related Content

Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor

Artificial Intelligence Greatly Speeds Radiation Therapy Treatment Planning

The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new

Recommended best practices for nuclear imaging departments under the COVIF-19 pandemic have been issues by the ASNC and SNMMI. #COVID19 #ASNC #SNMMI #Coronavirus #SARScov2

News | Coronavirus (COVID-19) | April 03, 2020

Best Practices for Nuclear Imaging During the Coronavirus (COVID-19) Pandemic

April 3, 2020 — A new guidance document on best practices to maintain safety and minimize contamination in nuclear im

Jeannie Danker, M.D. #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

Jeannie Danker, M.D. Photo courtesy of The Ohio State University Wexner Medical Center

News | Coronavirus (COVID-19) | April 03, 2020 | By Melinda Taschetta-Millane

The Industry Loses a Director of Radiology to COVID-19

April 3, 2020 — The radiology world has lost a dedicated leader due to...

An estimated 44 million people worldwide are currently living with Alzheimer’s disease, the most common form of dementia. About 5.8 million people in the United States live with the disease, where it is the sixth leading cause of death overall. While there is not yet a cure for Alzheimer’s, researchers are working to find treatment options to delay its onset and prevent it from developing.

Image courtesy of Insightec

Feature | Ultrasound Imaging | April 02, 2020 | By Katie Caron

Ultrasound’s Role in Alzheimer’s Treatment Research

An estimated 44 million people worldwide are currently living with...

An example of Philips’ TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal.

An example of Philips’ TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal. Photo by Dave Fornell

Feature | Radiology Imaging | April 02, 2020 | By Katie Caron

Emerging Trends in Radiology

A new year — and decade — offers the opportunity to reflect on the advancements and challenges of years gone by and p

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 Esaote won a tender launched by Consip on behalf of Civil Protection for the distribution of diagnostic equipment in Italy to face COVID-19 emergency.

Esaote won a tender launched by Consip on behalf of Civil Protection for the distribution of diagnostic equipment in Italy to face COVID-19 emergency.

News | Ultrasound Imaging | April 02, 2020

Esaote Delivers 103 portable Ultrasound Systems to Four Italian Regions

April 2, 2020 — Esaote, an Italian company among the world leader

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 Updated CT scoring criteria from AJR considers both lobe involvement and changes in CT findings to quantitatively and accurately evaluate the progression of COVID-19 pneumonia

CT scoring criteria were applied to images from sequential chest CT examinations. A, Initial chest CT image obtained 2 days after onset of symptoms shows small region of subpleural ground-glass opacities in right lower lobe, for CT score of 1. B, Chest CT image obtained on day 3 of treatment shows slightly enlarged region of subpleural ground-glass opacities with partial crazy-paving pattern and consolidation, for CT score of 3. C, Chest CT image obtained on day 5 of treatment shows partial resolution of consolidation, for CT score of 2. D, Chest CT image obtained on day 14 of treatment shows continued resolution of consolidation with minimal residual ground-glass opacities, for CT score of 1. Image courtesy of American Journal of Roentgenology (AJR)

News | Computed Tomography (CT) | April 02, 2020

New CT Scoring Criteria for Timely Diagnosis, Treatment of Coronavirus Disease

April 2, 2020 — Updated computed t...

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 the company is now offering a suite of AI solutions Vuno Med-LungQuant and Vuno Med-Chest X-ray for COVID-19, encompassing both lung X-ray and computed tomography (CT) modalities respectively all at once

News | Artificial Intelligence | April 02, 2020

Vuno offers a suite of AI solutions for COVID-19

April 2, 2020 — In the face of the COVID-19 pand

Improvised PPE face mask worn by a radiology technologist during rounds atSen. Gerardo M. Roxas Memorial District Hospital in Iloilo City, Philippines. #COVID19 #Coronavirus #SARScov2

Improvised PPE face mask worn by a radiology technologist during rounds at Sen. Gerardo M. Roxas Memorial District Hospital in Iloilo City, Philippines.

Feature | Coronavirus (COVID-19) | April 02, 2020 | Dave Fornell, Editor

Shortage of PPE Due to COVID-19 Driving Innovation by RT in The Philippines

There has been an extraordinary demand for personal protective equipment (PPE) with the rapid spread of the novel ...

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 New studies use SIRD model to forecast COVID-19 spread; examine patient CT scans to correlate clinical features with mortality

Fig 1. A sample scoring on CT images of a 63-year-old woman from mortality group demonstrated a total score of 63. It was calculated as: for upper zone (A), 3 (consolidation) × 3 (50–75% distribution) × 2 (both right and left lungs) + 2 (ground glass opacity) ×1 (< 25% distribution) × 2 (both right and left lungs); for middle zone (B), 3 (consolidation) × 2 (25–50% distribution) × 2 (both right and left lungs) + 2 (ground glass opacity) × 2 (25–50% distribution) × 2 (both right and left lungs); for lower zone (C), 3 (consolidation) × (2 (25–50% distribution of the right lung) + 3 (50–75% distribution of the left lung)) + 2 (ground glass opacity) × (2 (25–50% distribution of the right lung) + 1 (< 25% distribution of the left lung)) Yuan et al, 2020 (CC BY 4.0)

News | Coronavirus (COVID-19) | April 01, 2020

Two Studies Use SIRD Model to Forecast COVID-19 Spread

April 1, 2020 — A new study, ...